Table 4

Adjusted effectiveness comparison among biologic-naïve versus biologic-experienced individuals between treatments of interest and tumour necrosis factor (TNF)-alpha inhibitors

Biologic-naïve
(N=1774)
Biologic-experienced
(N=956)
Partially adjusted*Fully adjusted†Partially adjusted*Fully adjusted†
RR95% CIRR95% CIRR95% CIRR95% CI
All criteria
 TNFRefRefRefRef
 IL-12/230.600.43 to 0.850.630.45 to 0.890.750.53 to 1.060.770.55 to 1.09
 IL-17A0.900.57 to 1.421.020.65 to 1.581.140.79 to 1.651.240.86 to 1.79
 PDE40.870.74 to 1.020.920.78 to 1.090.640.44 to 0.910.670.46 to 0.96
Sans criterion for dose or frequency escalation
 TNFRefRefRefRef
 IL-12/230.600.43 to 0.830.630.45 to 0.880.700.50 to 0.990.730.52 to 1.02
 IL-17A1.030.69 to 1.541.170.80 to 1.721.330.96 to 1.841.441.03 to 1.99
 PDE40.830.70 to 0.970.880.75 to 1.040.600.42 to 0.860.630.44 to 0.90
  • *Adjusted for sex, age, race or ethnicity.

  • †Adjusted for sex, age, race or ethnicity, educational level, Deyo Charlson Comorbidity, sDMARD, oral glucocorticoid, NSAID, opioid, number of inpatient stays, number of ED stays, COPD, asthma, fibromyalgia, any diabetes, any mood disorder and major depressive disorder.

  • CI, confidence interval; COPD, chronic obstructive pulmonary disease; ED, emergency department; IL, interleukin; NSAID, non-steroidal anti-inflammatory drugs; PDE4, phosphodiesterase-4; sDMARD, synthetic disease-modifying antirheumatic drugs.